These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 15133486)
1. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Sohn SK; Kim DH; Kim JG; Lee NY; Suh JS; Lee KS; Lee KB Bone Marrow Transplant; 2004 Jul; 34(1):63-8. PubMed ID: 15133486 [TBL] [Abstract][Full Text] [Related]
2. New clinical grading system for chronic GVHD predicts duration of systemic immunosuppressive treatment and GVHD-specific and overall survival. Kim ST; Jung CW; Lee J; Kwon JM; Oh SY; Park BB; Lee HR; Kim HJ; Kim K; Kim WS; Ahn JS; Kang WK; Park K Bone Marrow Transplant; 2007 Jun; 39(11):711-6. PubMed ID: 17417662 [TBL] [Abstract][Full Text] [Related]
3. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases. Sohn SK; Kim DH; Kim JG; Sung WJ; Baek JH; Lee NY; Won DI; Suh JS; Lee KS; Lee KB Eur J Haematol; 2004 Jun; 72(6):430-6. PubMed ID: 15128422 [TBL] [Abstract][Full Text] [Related]
4. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214 [TBL] [Abstract][Full Text] [Related]
5. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271 [TBL] [Abstract][Full Text] [Related]
6. Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study. Heldal D; Brinch L; Tjønnfjord G; Solheim BG; Egeland T; Albrechtsen D; Aamodt G; Evensen SA Bone Marrow Transplant; 2003 Aug; 32(3):257-64. PubMed ID: 12858196 [TBL] [Abstract][Full Text] [Related]
7. Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset. Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Ahn JS; Kim YK; Yang DH; Lee JJ; Kim HJ; Choi YJ; Shin HJ; Chung JS; Cho GJ; Sohn SK Bone Marrow Transplant; 2010 Oct; 45(10):1540-5. PubMed ID: 20190848 [TBL] [Abstract][Full Text] [Related]
8. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT. Scholl S; Mügge LO; Issa MC; Kasper C; Pachmann K; Höffken K; Sayer HG Bone Marrow Transplant; 2005 Jan; 35(2):183-90. PubMed ID: 15531897 [TBL] [Abstract][Full Text] [Related]
9. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119 [TBL] [Abstract][Full Text] [Related]
11. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation. Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704 [TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
13. Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome. Yüksel M; Baron E; Camouse M; Cooper BW; Lazarus HM; Gerson SL; Laughlin MJ; Cooper KD; Gilliam A; Fu P; Stevens S; Koç ON Biol Blood Marrow Transplant; 2006 Jun; 12(6):665-71. PubMed ID: 16737940 [TBL] [Abstract][Full Text] [Related]
14. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896 [TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors. Kang BW; Moon JH; Chae YS; Kim JG; Jung JS; Cho GJ; Jo DY; Kim YK; Kim HJ; Ryoo HM; Eom HS; Lee SM; Joo YD; Won JH; Park MR; Kim MK; Hyun MS; Sohn SK Ann Hematol; 2010 Aug; 89(8):813-20. PubMed ID: 20177897 [TBL] [Abstract][Full Text] [Related]
16. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257 [TBL] [Abstract][Full Text] [Related]
17. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic peripheral blood stem cell transplantations in children--a single center experience. Sufliarska S; Horáková J; Bodová I; Martinka J; Hrubisko M; Kovács L; Jancovicová K; Lukác J Neoplasma; 2004; 51(2):110-6. PubMed ID: 15190420 [TBL] [Abstract][Full Text] [Related]
20. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]